Fellow

Professor of Pulmonary Pharmacology at the University of Glasgow, Mandy Maclean is distinguished for her research on the pathogenesis and treatment of pulmonary arterial hypertension. She is regarded as an international expert in this field and is one of the few basic science researchers that regularly contribute to the triennial workshops hosted by the World Health Organisation. 60-80% of PAH patients are female and Professor Maclean identified the oestrogen metabolising enzyme CYP1B1 as a novel target for the treatment of PAH that can be modulated. She has also characterised four novel models of serotonin and oestrogen-dependent PAH that mimic the development of pulmonary hypertension only in females.